City
Epaper

Researchers find a new treatment for rare muscular disease

By ANI | Published: April 16, 2021 10:55 AM

University of Cincinnati researchers have found a newer, more effective treatment for the disease Pompe that could become the new standard of care for the rare condition.

Open in App

University of Cincinnati researchers have found a newer, more effective treatment for the disease Pompe that could become the new standard of care for the rare condition.

Rare diseases are sometimes the most difficult to treat because of a lack of research and fewer participants to study. An example would be those who have Pompe disease, a genetic condition when a body can't make a protein that breaks down a complex sugar, called glycogen, for energy. Too much glycogen builds up and damages muscles and organs. The disease causes muscle weakness and trouble breathing and can affect the heart and muscles.

H Kushlaf, MD, an associate professor in both the Department of Neurology and Rehabilitation Medicine and the Department of Pathology and Laboratory Medicine at UC and principal investigator of a study led at UC, will present findings on this new treatment virtually at the American Academy of Neurology on April 20.

Kushlaf, a UC Health physician, says Pompe disease affects about 1 in 40,000 people in the United States. It can impact children, but it can also present later in life as well. Left untreated, it can result in progressive loss of function of muscles in limbs and respiration leading to the need for wheelchair use and respiratory support.

"In this clinical trial, we tested a new drug, or enzyme replacement therapy (avalglucosidase alfa), to see if it was more effective and safer than the currently approved therapy, also an enzyme replacement therapy, in patients with late-onset Pompe disease," he says. "It turns out that it is safer and more effective than the current FDA-approved therapy. This new enzyme will likely become the standard of care for patients with the disease and has already been submitted for Food and Drug Administration approval. This is a big deal for patients with this rare disease, as t-PA was for stroke."

This study was double-blinded, meng neither the participants nor the researchers knew which treatment was being administered via an infusion. In 51 patients who received the new treatment, researchers saw an improvement in respiratory muscle function, endurance and muscle strength, in addition to overall better quality of life, when compared to patients on the current standard of care therapy.

"These results are extremely promising for finding a new and effective treatment for this disease," adds Kushlaf, who is also a member of the UC Gardner Neuroscience Institute. "With these results, we can take the next steps in having it used widely in this patient population, improving their outcomes and giving them a better life."

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Department of neurology and rehabilitation medicineUniversity Of CincinnatiUniversity of cincinnati college of medicine
Open in App

Related Stories

TechnologyResearchers discover distinct patterns of pre-existing brain health characteristics in stroke patients

TennisItalian Open: Tsitsipas, Djokovic, Rune advance to quarterfinals

TechnologyResearchers find how new strategy to treat cancer

TechnologyNew study compares cost-effectiveness of blood clot treatments in cancer patients

TechnologyStudy: Head, neck cancer treatment can be improved by immunotherapy drug

Technology Realted Stories

TechnologyNew Vitamin C-rich bandage to boost burn healing

TechnologyIndian tech companies begin to create global impact: SAP's Manish Prasad

TechnologyHow do Different VN88 Rezence Wireless Charging Technologies Impact Electromagnetic Interference?

TechnologyStudy shows how E. coli causes urinary tract infections

TechnologyOver 80,000 tech employees lost jobs globally in first four months this year in 279 firms: Report